GSK, Novartis launch US$3.6m project to support high-quality genetic scientific research in Africa

AFRICA – GlaxoSmithKline plc (GSK), a British multinational pharmaceutical, and Novartis International AG is a Swiss multinational pharmaceutical, have announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics. The Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT), with a combined funding commitment of US$3.6 million over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to…

Read More

Several American healthcare providers partner to launch 20 lifesaving cancer treatments in Africa

SUB SAHARAN AFRICA – The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) has announced agreements with pharmaceutical companies Pfizer, Novartis and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements. “With the rapidly growing burden of cancer in Africa, it is crucial that we improve and expand access to high-quality, affordable treatment. These agreements build on those announced in 2017 that have…

Read More

mPharma raises US$17m funding round led by Novartis Ventures

GHANA – mPharma, a tech-enabled healthcare company developing a more efficient supply chain for pharmaceutical products across Africa, has completed a US$17 million fundraising round.   The Accra based medicine benefits and inventory manager, which was founded in 2013 by Gregory Rockson, Daniel Shoukimas and James Finucane, aims to increase patient access to affordable high-quality medications.   According to Quartz Africa, Helena Foulkes, former president of CVS, the largest pharmacy retail chain in the US, had been appointed to the company’s board.    The investment round was led by Novastar Ventures with participation…

Read More

54gene secures US$15m Series A funding round to scale operations

NIGERIA – 54gene, an African genomics research, services, and development startup, has closed a Series A round of US$15 million to allow it to scale operations.The startup raised a US$4.5 million seed round last year, and has now secured US$15 million in Series A capital in a round led by Adjuvant Capital, a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation. The round included participation from Raba Capital, V8 Capital, and Ingressive Capital, as well as follow-on investment from Y Combinator,…

Read More